Tacrolimus
ApprovedTerminated 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Kidney Transplantation
Conditions
Kidney Transplantation
Trial Timeline
May 1, 2010 → Oct 1, 2012
NCT ID
NCT02963103About Tacrolimus
Tacrolimus is a approved stage product being developed by Astellas Pharma for Kidney Transplantation. The current trial status is terminated. This product is registered under clinical trial identifier NCT02963103. Target conditions include Kidney Transplantation.
What happened to similar drugs?
20 of 20 similar drugs in Kidney Transplantation were approved
Approved (20) Terminated (0) Active (0)
✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00189761 | Phase 2 | Completed |
| NCT00293930 | Phase 3 | Completed |
| NCT00189787 | Phase 2 | Completed |
| NCT00189722 | Phase 2 | Completed |
| NCT03465969 | Approved | Completed |
| NCT02555787 | Pre-clinical | Completed |
| NCT02147938 | Pre-clinical | Completed |
| NCT02143479 | Pre-clinical | Completed |
| NCT02159651 | Pre-clinical | Completed |
| NCT02057484 | Pre-clinical | Completed |
| NCT02377609 | Pre-clinical | Terminated |
| NCT01745159 | Approved | Completed |
| NCT01511003 | Approved | Completed |
| NCT01316133 | Approved | Terminated |
| NCT01410162 | Approved | Completed |
| NCT02963103 | Approved | Terminated |
| NCT01224041 | Approved | Completed |
| NCT01224418 | Approved | Completed |
| NCT00504348 | Phase 2/3 | Completed |
| NCT01410747 | Pre-clinical | Completed |
Competing Products
20 competing products in Kidney Transplantation